Business Wire

RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients

This Clinical Trial will Show Preliminary Safety and Probable Benefit of TETRANITE ® for Replacing the Use of Metal Plates and Screws LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it ...
MarketWatch

FDA Greenlights RevBio's Pivotal Clinical Trial for its Cranial Flap Bone Glue

RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use TETRANITE(R) to ...
Hosted on MSN

RevBio receives FDA clearance for cranial bone glue trial

US-based bone adhesive company RevBio has received the Food and Drug Administration’s (FDA) investigational device exemption (IDE) approval to conduct a clinical trial of its cranial flap bone glue.
Morningstar

FDA Greenlights RevBio’s Pivotal Clinical Trial for its Cranial Flap Bone Glue

This clinical trial is designed to demonstrate that TETRANITE® can immediately fixate cranial flaps and enable bone fusion in craniotomy and cranioplasty procedures to improve cosmesis, increase flap ...
Rutland Herald

FDA Greenlights RevBio’s Pivotal Clinical Trial for its Cranial Flap Bone Glue

RevBio, Inc., announced that it has received investigational device exemption (IDE) approval from the FDA to conduct a multi-center randomized controlled pivotal clinical trial to use TETRANITE® to ...